Clinical trial
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in…
NCT00312728 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00312728 |
|---|---|
| Title | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) |
| Official title | A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer, Brain Neoplasms |
| Intervention type | Drug |
| Interventions | bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents |
| Enrollment | 115 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Apr 11, 2006 |
| Last update posted | Jan 6, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: